Zimbabwe has turned down a substantial American health deal valued at 367 million US dollars (272 million pounds) over five years because of the United States' demand for sensitive biological samples.
The decision came to light following a internal memorandum dated December was leaked, indicating that President Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government representative has since stated that the United States was seeking biological samples for scientific study and profit while refused to share the benefits from any future treatments.
"We are forced to start the challenging and unfortunate process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had provided over $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged more talks to reach a agreement agreeable to all parties so the nation's vital HIV programme can be sustained.
Wider Background
This development comes after a similar case in neighbouring Kenya, where a high court suspended a related deal with the US after concerns were raised about the security of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump argued its expenditure was "wasteful" and his administration was seeking direct bilateral deals to boost transparency and accountability.
As per statements, 16 nations in Africa have so far signed similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation might have yielded extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently on HIV treatment through US-supported programmes," the Ambassador said.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, with no equivalent promise of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"In essence, our country would supply the basic resources for scientific discovery with no certainty that the end products would be available to our people should a new health crisis arise."
National Interest and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were undermining frameworks previously established via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to manage future pandemics.
"This system is designed to ensure that when a country contributes its data, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," he added.
"We are open to ongoing dialogue with our American counterparts on how future co-operation could be structured in a way that respects the independence and interests of both nations."
Health Experts Response
A leading public health body stated it recognised the official position, but recommended that negotiations should continue considering a large portion of the country's HIV programmes depended on foreign aid.
"If specific concerns arise, such as those involving data governance or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," it added.
This impasse emphasises the complex debate between accepting crucial foreign assistance and safeguarding a country's data in an increasingly data-driven world.